Keynote224. Patients receiving pembrolizumab monotherapy for previously untreated advanced hepatocellular. As you probably already know, dr.

Pembrolizumab received accelerated approval in november 2018 for patients with hcc who had previously been treated with sorafenib, based on orr and. Nagc24 closing keynote how to be extraordinary and happy.